Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 10 | 2018 | 76 | 2.030 |
Why?
|
| Peer Group | 1 | 2024 | 156 | 0.860 |
Why?
|
| Focus Groups | 1 | 2024 | 348 | 0.840 |
Why?
|
| Schizophrenic Psychology | 4 | 2018 | 17 | 0.790 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 317 | 0.740 |
Why?
|
| Appetite Depressants | 3 | 2018 | 9 | 0.700 |
Why?
|
| Antipsychotic Agents | 6 | 2013 | 68 | 0.670 |
Why?
|
| Satiation | 1 | 2018 | 9 | 0.630 |
Why?
|
| Oxytocin | 1 | 2018 | 25 | 0.610 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2013 | 40 | 0.520 |
Why?
|
| Piperidines | 2 | 2013 | 77 | 0.520 |
Why?
|
| Pyrazoles | 2 | 2013 | 85 | 0.510 |
Why?
|
| Periodontal Diseases | 1 | 2014 | 49 | 0.450 |
Why?
|
| Satiety Response | 1 | 2013 | 5 | 0.450 |
Why?
|
| Overweight | 2 | 2013 | 247 | 0.440 |
Why?
|
| Double-Blind Method | 5 | 2018 | 286 | 0.340 |
Why?
|
| Patient Compliance | 1 | 2010 | 212 | 0.340 |
Why?
|
| Brain | 3 | 2018 | 1346 | 0.330 |
Why?
|
| Stress, Psychological | 1 | 2014 | 583 | 0.310 |
Why?
|
| Depression | 1 | 2014 | 712 | 0.300 |
Why?
|
| Exercise | 2 | 2011 | 613 | 0.270 |
Why?
|
| Baltimore | 1 | 2024 | 52 | 0.240 |
Why?
|
| Eating | 2 | 2018 | 166 | 0.240 |
Why?
|
| Male | 13 | 2024 | 20025 | 0.220 |
Why?
|
| Female | 13 | 2024 | 20969 | 0.210 |
Why?
|
| Middle Aged | 11 | 2018 | 10129 | 0.210 |
Why?
|
| Psychotic Disorders | 2 | 2012 | 55 | 0.190 |
Why?
|
| Adult | 11 | 2018 | 11712 | 0.190 |
Why?
|
| Clozapine | 2 | 2011 | 17 | 0.190 |
Why?
|
| Humans | 15 | 2024 | 37093 | 0.180 |
Why?
|
| Adolescent | 2 | 2024 | 5363 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2013 | 854 | 0.170 |
Why?
|
| Pilot Projects | 4 | 2018 | 661 | 0.170 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2018 | 9 | 0.160 |
Why?
|
| Central Nervous System Agents | 1 | 2018 | 7 | 0.160 |
Why?
|
| Acetamides | 1 | 2018 | 11 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 18 | 0.160 |
Why?
|
| Mental Disorders | 2 | 2013 | 309 | 0.160 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 79 | 0.160 |
Why?
|
| Taste | 1 | 2018 | 41 | 0.150 |
Why?
|
| Smell | 1 | 2018 | 36 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 108 | 0.150 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2018 | 77 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 864 | 0.150 |
Why?
|
| Leptin | 1 | 2018 | 118 | 0.140 |
Why?
|
| Insulin | 1 | 2018 | 236 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2018 | 353 | 0.130 |
Why?
|
| Cocaine | 1 | 2018 | 232 | 0.130 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 24 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 70 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 98 | 0.110 |
Why?
|
| Body Weight | 2 | 2013 | 434 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 97 | 0.110 |
Why?
|
| Drug Inverse Agonism | 1 | 2013 | 2 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 1742 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2014 | 484 | 0.110 |
Why?
|
| Diet, Gluten-Free | 1 | 2012 | 2 | 0.110 |
Why?
|
| Gliadin | 1 | 2012 | 3 | 0.110 |
Why?
|
| Transglutaminases | 1 | 2012 | 8 | 0.110 |
Why?
|
| Energy Intake | 1 | 2013 | 170 | 0.100 |
Why?
|
| Antibodies | 1 | 2012 | 141 | 0.100 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2011 | 4 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 601 | 0.100 |
Why?
|
| Propylamines | 1 | 2011 | 6 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2011 | 15 | 0.100 |
Why?
|
| Pleasure | 1 | 2011 | 4 | 0.100 |
Why?
|
| Maryland | 4 | 2012 | 53 | 0.090 |
Why?
|
| Marijuana Abuse | 1 | 2012 | 91 | 0.090 |
Why?
|
| Affective Symptoms | 1 | 2011 | 57 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 157 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2010 | 208 | 0.090 |
Why?
|
| Health Behavior | 1 | 2014 | 537 | 0.090 |
Why?
|
| Young Adult | 2 | 2018 | 4268 | 0.090 |
Why?
|
| Alcoholism | 1 | 2012 | 240 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2012 | 253 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2013 | 1908 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 664 | 0.060 |
Why?
|
| Smoking | 1 | 2009 | 940 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1067 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2012 | 2026 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2011 | 117 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2011 | 259 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 550 | 0.040 |
Why?
|
| Raclopride | 1 | 2018 | 8 | 0.040 |
Why?
|
| Comorbidity | 2 | 2012 | 623 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 55 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 141 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 80 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 85 | 0.040 |
Why?
|
| Dopamine | 1 | 2018 | 245 | 0.040 |
Why?
|
| Age Factors | 2 | 2010 | 1033 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1039 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 3562 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2011 | 7 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2011 | 24 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 325 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 148 | 0.020 |
Why?
|
| Autopsy | 1 | 2010 | 43 | 0.020 |
Why?
|
| Attention | 1 | 2011 | 156 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 225 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 267 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 156 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 308 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 318 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2009 | 124 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 455 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 441 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 534 | 0.020 |
Why?
|
| Aged | 2 | 2010 | 6741 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 935 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 898 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 974 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 885 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1492 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1455 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 730 | 0.010 |
Why?
|
| United States | 1 | 2010 | 4223 | 0.010 |
Why?
|